Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, is recruiting adult patients for a phase I clinical trial designed to evaluate the safety of KPG-818 and how participants with specific hematological malignancies respond to the immunotherapy. KPG-818 is an investigational drug designed to modulate the immune system, potentially blocking cancer cells from growing and spreading. Results from the study will help to identify a recommended dose to evaluate in the next phase of this trial.
A hematological malignancy is a blood cancer that begins in the bone marrow or in the cells of the immune system. There are three common types of blood cancers: myeloma, lymphoma and leukemia. In most blood cancers, the normal blood cell development process is interrupted by the growth of abnormal (cancer) cells. Cancerous cells prevent blood from fighting off infections or preventing bleeding.
Patients with multiple myeloma, chronic lymphocytic leukemia and several types of lymphoma may be eligible to participate in the study.
This clinical trial consists of two parts:
- Dose escalation to determine dose limited toxicity (DLT) in 11-15 study participants.
- Dose expansion to determine the recommended Phase 2 dose (RP2D) in 18-30 participants.
Providence is one of only three locations in the United States currently recruiting for this clinical trial. John E. Godwin, M.D., MS, oncologist and medical director, Hematologic Malignancies Program at Providence, is the principal investigator. Get the full details here:
For more information about this study or to refer patients, please contact our Clinical Research office:
See related studies
There are nearly 20 hematological studies currently open to enrollment at Providence Cancer Institute of Oregon. New research studies are added frequently.
See all studies in all cancer types at Providence Cancer Institute.
Care for people with blood cancers and disorders
Providence Hematologic Malignancies Program offers compassionate care for cancers of the blood, bone marrow and lymph nodes, including Hodgkin and non-Hodgkin lymphomas, leukemia, myeloma, and the myelodysplastic syndromes. We combine the most advanced therapies, breakthrough research and multidisciplinary care to fight cancer. We are among the few elite centers capable of administering adoptive cellular therapies such as chimeric antigen receptor (CAR) T-cell therapy and tumor infiltrating lymphocytes (TIL). Many of our clinical trials are first-in-human studies of new immune therapies aimed at maximizing the potential of the immune system to destroy cancer.
Want to receive our newsletters and important announcements? Subscribe here.